Company Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Amarin Corporation plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 12:12:41 2024-04-24 pm EDT			5-day change	1st Jan Change
0.865 ^USD	-2.07%		-5.63%	-0.52%

Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT
Apr. 18	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

USD in Million	2022	Weight	2023	Weight	Delta
Vascepa 93.0 %	367	99.3 %	285	93.0 %	-22.16%
Licensing 7.0 %	3	0.7 %	22	7.0 %	+705.82%

Managers	Title	Age	Since
Patrick Holt CEO	Chief Executive Officer	52	23-07-17
Thomas Reilly DFI	Director of Finance/CFO	52	22-06-19
Jonathan Provoost CMP	Compliance Officer	55	Nov. 14
Nabil A. Abadir CTO	Chief Tech/Sci/R&D Officer	-	22-03-31
Derek Kalinowski COO	Chief Operating Officer	-	11-03-31
David Keenan CTO	Chief Tech/Sci/R&D Officer	-	22-04-30
Steven Ketchum CTO	Chief Tech/Sci/R&D Officer	59	12-02-15
Aaron Berg PRN	Corporate Officer/Principal	61	12-10-31

Members of the board	Title	Age	Since
Louis Sterling BRD	Director/Board Member	45	23-02-27
Odysseas Kostas CHM	Chairman	49	23-02-27
Keith Horn BRD	Director/Board Member	66	23-02-27
Mark Dipaolo BRD	Director/Board Member	53	23-02-27
Diane Sullivan BRD	Director/Board Member	62	23-02-27
Patrice Bonfiglio BRD	Director/Board Member	40	23-02-27
Patrick Holt CEO	Chief Executive Officer	52	23-07-17
Paul Cohen BRD	Director/Board Member	49	23-02-27
Oliver O’Connor BRD	Director/Board Member	62	23-04-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	411,187,269	381,305,082 ( 92.73 %)	9,317,202 ( 2.266 %)	92.73 %

Name	Equities	%	Valuation
Sarissa Capital Management LP 8.150 %	33,470,000	8.150 %	30 M $
Sarissa Capital Management LP 6.051 %	24,850,623	6.051 %	22 M $
Kynam Capital Management LP 2.928 %	12,022,957	2.928 %	11 M $
Eversept Partners LP 1.484 %	6,095,505	1.484 %	5 M $
Morgan Stanley Capital Services LLC 1.355 %	5,563,083	1.355 %	5 M $
DG Capital Management LLC 1.316 %	5,405,438	1.316 %	5 M $
Two Sigma Investments LP 0.7754 %	3,184,293	0.7754 %	3 M $
Tang Capital Management LLC 0.7516 %	3,086,544	0.7516 %	3 M $
Two Sigma Advisers LP 0.6642 %	2,727,602	0.6642 %	2 M $
Millennium Management LLC 0.6182 %	2,538,596	0.6182 %	2 M $

Name	Equities	%	Valuation
Aaron Berg 0.6582 %	2,380,807	0.6582 %	2 M $
Steven Ketchum 0.6532 %	2,362,567	0.6532 %	2 M $
Karim Mikhail 0.2186 %	790,742	0.2186 %	704 551 $
Patrick Holt 0.0869 %	314,426	0.0869 %	280 154 $
Thomas Reilly 0.0595 %	215,365	0.0595 %	191 890 $
Louis Iii Sterling 0.0182 %	65,673	0.0182 %	58 515 $
Louis Sterling 0.0182 %	65,673	0.0182 %	58 515 $
Wall Street Management Corp. 0.001106 %	4,000	0.001106 %	3 564 $
Odysseas Kostas 0.000000 %	0	0.000000 %	- $
Keith Horn 0.000000 %	0	0.000000 %	- $

Amarin Corp. Plc

Iconic Offices, The Greenway Block C Ardilaun Court, 112–114

2, Dublin

+353 0 166 99020

http://www.amarincorp.com

Name	Category and Sector
Corsicanto II DAC	Finance/Rental/Leasing

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.8833 USD

Average target price

1.083 USD

Spread / Average Target

+22.65%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AMARIN CORPORATION PLC	+1.53%	363M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+2.97%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.35%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs